TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway
Oncology Reports · 2023
DOI: 10.3892/or.2023.8521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology Reports, 2023. Verfasst von Zhangxian Xiao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning 110122, P.R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 17-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Hospital and College of Basic Medical Sciences, China Medical University, Shenyang, Liaoning 110122, P.R. China.
- Department of Pathology, The First Hospital of China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China.
Zitieren
APA
Xiao, Z., Li, M., Zhang, X., Rong, X., & Xu, H. (2023). TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. Oncology Reports. https://doi.org/10.3892/or.2023.8521
Vancouver
Xiao Z, Li M, Zhang X, Rong X, Xu H. TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway. Oncology Reports. 2023. doi:10.3892/or.2023.8521
BibTeX
@article{Xiao2023,
author = {Xiao, Zhangxian and Li, Mingxi and Zhang, Xiaoqian and Rong, Xuezhu and Xu, Hongtao},
title = {TRIP13 overexpression promotes gefitinib resistance in non‑small cell lung cancer via regulating autophagy and phosphorylation of the EGFR signaling pathway},
journal = {Oncology Reports},
year = {2023},
doi = {10.3892/or.2023.8521}
}
EUVIMED